Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Bringing it pink current would add a great deal of value as well
It is really the main objective to have a value driven company put within the shell.
Thanks. So what is the objective here as to next steps (assuming Omni is approved by the court as the custodian). Obviously, a Reverse merger makes sense; but what are the other possibilities to increase the stock value?
Tomorrow is the court date. Should get things rolling finally. GLTA
We are still aways away from a reverse merger possibility but the likely hood of omni corp being granted custody would have to be near 95%. This is based on the dozens of custodianships that I've watched and participated in. Best of luck to us all $OVIT
Thanks for posting the court date.
Can anybody who is familiar with these type of reverse mergers handicap a likely outcome? Do we have any similar examples that align to this exact situation and what was that outcome?
It looks like the stock price is in control of a very few buyers/holders as it has moved in very slow fashion; it has moved upward over a long period of time.
Really looking forward to this one. :)
OMNI seems to specialize in low floaters. I've been following since first tweet.
My pleasure B, I grabbed a position today... with this share structure, we should do very well if granted
Thanks for the info StockHobit. I appreciate it! It's been a long time coming...
That is exactly what they do. :)
They go to court hoping to be granted custody of the defunct company. If granted they will usually do what needs to be done to clean up the company and then sell it to a private co. that will merge into the public shell
When I look at Omni Corporate Solutions Twitter page I see that they have announced the same news for other companies like $ZHUD, $CHME, $TURA, $CLPE, etc. Can someone please elaborate on what exactly Omni Corporate Solutions does? Does this company specialize in reverse shell mergers and then find other private companies that want to go public? I'm trying to understand exactly what this news means.
Any information would be appreciated.
Omni Corporate Solutions LLC Application for Appointment of Custodian for OncoVista Innovative Therapies Inc., $OVIT has been filed with the courts today on 4/26/2021. Case # A-21-833640-C. We should get a court date in the next few days, we will post when it becomes available.
Some investors have an interest to keep the trading active here (must be to keep the minimum SEC trading requirements for the listing satisfied). Also, I see a potential cup and handle forming; it appears its in the final process of finishing out the right side of the handle. If so, look for a volume increase and breakout above $.05 ish.
It's only a matter of time before someone acquires this company to do a reverse shell merger. This stock has been being accumulated for quite some time now and the buyers are being very patient making sure they get in cheap. My bet is reverse shell merger happens this year, especially since the SPAC industry is on fire!!
SPAC’s are on fire
It's back to life.
I wonder if there will be a reverse shell merger into a new company.
Oooh Yaaa! Ugh! Big volume!
Uh Oh, someone is selling! Someone knows something! Could it be, that they know what we already know, that OVIT is out of business and dormant? Do'h! OVIT can stay dormant forever, do'h! waaaaa!~
Well, OVIT jumped the shark years ago, it's been over and done with a long time ago.
I don’t recall OVIT ever trading pre market
Had premarket trading volume today (I have never seen it this active...before the market opened).
@gi197845 so you’re saying they might have the virus cure? Great!
Still a dormant pharma company, how dumb! When will this POS be revere shell merged into a new company that want's to go public, what a damned joke!!!
Down she goes and where she stops, nobody knows!
Oh wait, it's an indefinite dormancy, which at this point, is still the same basic result as bankruptcy.
OVIT failed with Oncology, so it's time to sell this shell to a new company with a different business model.
LOL, that would be a no!
Fool me once, shame on you!
Fool me twice, shame on me!
I’ll buy however many shares you have @ .01. Pocket yourself some $$$$$!
Followers
|
24
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
772
|
Created
|
01/16/10
|
Type
|
Free
|
Moderators |
OncoVista Innovative Therapies, Inc. (OVIT)
Please see the bottom of the iBox for a contrary view on this stock.
http://www.oncovista.com/
Company Information:
OncoVista Innovative Therapies, Inc.
14785 Omicron Drive
Suite 104
San Antonio,, TX 78245
Phone: 210-677-6000
CIK: 0001094847
The latest 10Q can be found here: http://filings.issuerdirect.com/data/1094847/000114420411063209/v240119_10q.pdf
Link to clinical trials register: http://www.clinicaltrials.gov/ct2/results?term=cordycepin
Neither of the two cordycepin studies registered with clinical.trials.gov has been updated for over two years, which is a breach of registration conditions.
OncoVista Innovative Therapies, Inc., is a bio-pharmaceutical company that claims to be dedicated to providing innovative, safe and efficacious treatments for cancer through the use of biomarkers in order to extend and improve the quality of life for patients.
Based in San Antonio, Texas, OncoVista was incorporated in 2004 and says it utilizes state-of-the-art drug discovery technologies, innovative clinical development and registration strategies as well as emerging technologies to bring to market new, safe and highly effective anti-cancer drugs. Although no such drugs have yet been brought to market, and the "incubator" behind Onco Vista, Technology Innovations, LLC, has a long and inglorious history of transferring monies from its publicly held spin-offs such as Biophan and Natural Nano into private hands.
Management:
http://www.oncovista.com/index.php?option=com_content&task=view&id=67
Claims made by Onco Vista regarding its Core Capabilities for Accelerated Drug Development
Lipitek International
Well-equipped research labs for chemical synthesis and biological evaluations; GMP manufacturing suite
UT Health Science Center (Prof. Luduena)
Biological evaluation and testing of new anti-mitotics, including tubulin isotype-specific assays
University of Alberta (Prof. Tuszynski)
Molecular modeling, computer simulation of new molecules, molecule design and in silico screening
AAI Oncology (Paris)
Global oncology-focused clinical Contract Research Organization (CRO)
Cancer Therapy & Research Center (CTRC)/Institute for Drug Development (IDD)
In vitro and in vivo capabilities; Phase I/II clinical trials
Other Local Resources (nothing to do with Onco Vista per se: probably included here to give an impression of referred respectability).
Southwest Oncology Group
Southwest Foundation for Biomedical Research
Press Releases:
http://www.oncovista.com/index.php?option=com_content&task=view&id=91
http://finance.yahoo.com/q/h?s=OVIT.OB+Headlines
-----------------------
AdnaGen
News from AdnaGen site, which is majority owned by OVIT
http://www.adnagen.com/HTML_Dateien/e_news_news.htm
OVIT used to own 78% of the issued and outstanding shares of AdnaGen*
* On November 2, 2010, OncoVista Innovative Therapies, Inc. (the "Company") entered into a Stock Purchase Agreement with Alere Holdings Bermuda Limited Canon's Court ("Alere Holdings"), whereby the Company sold all of its shares, representing approximately 78.01% of the total issued and outstanding shares, of its majority-owned German operating subsidiary AdnaGen AG ("AdnaGen"). Under the terms of the Stock Purchase Agreement, the Company and the other AdnaGen shareholders agreed to sell their respective shares of AdnaGen, and all AdnaGen related business assets, to Alere Holdings in consideration of: (i) a $10,000,000 up-front; (ii) $10,000,000 in potential milestone payments contingent upon the achievement of various balance sheet objectives within 24 months; and (iii) up to $63,000,000 in potential milestone payments contingent upon the achievement of various clinical, regulatory and sales objectives within 36 months (collectively, the "Consideration"). The Company is entitled to receive its pro rata portion of approximately 78.01% of all Consideration.http://www.sec.gov/Archives/edgar/data/1094847/000114420410057309/v200923_8k.htm
----------------------
Filings:
Share Structure:
Authorized Shares
147,397,390 as of September 30, 2011
Outstanding Shares
21,370,725 as of September 30, 2011
All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.
Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement: http://investorshub.advfn.com/boards/complex_terms.asp
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |